CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,013 enrolled
Drug / intervention
peginterferon alfa-2a [Pegasys] +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01429792
NCT01429792Phase 4Completed
CompareCT.gov

A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 & 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin)

Hoffmann-La Roche·interventional·Posted Sep 7, 2011·Updated Oct 23, 2018

In Brief

A Phase 4 clinical trial evaluating peginterferon alfa-2a [Pegasys] and ribavirin [Copegus] for Hepatitis C, Chronic. Completed, enrolled 1,013 participants across 26 sites.

Detailed Summary

This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral Copegus for 24 weeks (genotype 2 \& 3) or 48 weeks (genotype 1 \& 4). Patients identified as slow responders/non-rapid virological responders will be eligible for an additional 24 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesIsrael
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2011
Enrollment StartSep 25, 2008
Primary CompletionJun 10, 2013
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 14.8 years ago

Interventions

peginterferon alfa-2a [Pegasys]drug

standard treatment, subcutaneously weekly

ribavirin [Copegus]drug

standard treatment, orally daily